6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-16), Foghorn Therapeutics's 6-1 Month Momentum % is 69.34%.
The industry rank for Foghorn Therapeutics's 6-1 Month Momentum % or its related term are showing as below:
FHTX's 6-1 Month Momentum % is ranked better than 85.77% of 1518
companies
in the Biotechnology industry
Industry Median: -3.04
vs FHTX: 69.34
Competitive Comparison
For the Biotechnology subindustry, Foghorn Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Foghorn Therapeutics 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Foghorn Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Foghorn Therapeutics (Foghorn Therapeutics) Business Description
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FHTX has been successfully added to your